Vascular Inflammation in Psoriasis Trial (The VIP Trial)
Status:
Completed
Trial end date:
2016-10-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of adalimumab (Humira), when compared to
NB-UVB (narrow-band ultraviolet B) phototherapy or placebo (an inactive substance that may
resemble an active substance but has no medical value) injection. The study will compare the
effects of each on systemic inflammation and cardiovascular disease risk factors in subjects
diagnosed with moderate to severe psoriasis.
This study will look for systemic vascular inflammation in subjects with a test called
FDG-PET/CT (Fluorodeoxyglucose-positron emission tomography/computed tomography). The study
will also look for cardio metabolic (heart disease and metabolic factors such as diabetes)
identifiers in the blood. A blood sample will be taken that will look for these markers
identifying high cholesterol, cholesterol efflux function (the ability of cholesterol to move
in the body), metabolic factors, and inflammation.
This study will also assess the effect of adalimumab (Humira), when compared to NB-UVB
phototherapy or placebo injection on psoriasis activity and severity. The study will also
compare the safety of adalimumab (Humira) to NB-UVB phototherapy or placebo injection. This
study will also evaluate subjects' reported outcomes through a questionnaire that will assess
quality-of-life in subjects living with psoriasis.